Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Abraham

Showing results (631-640 of 932) with videos related to

Pageof 94
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|January 3, 2007
Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failureCharles T Klodell, David C McGiffin, Barry K Rayburn, et al.
Journal of the American College of Cardiology|July 12, 2008
Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF programGregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Heart Rhythm|November 29, 2021
The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studiesEugene S Chung, Michael R Gold, William T Abraham, et al.
Journal of Cardiac Failure|November 13, 2007
Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HFGregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Cardiology|January 1, 1995
Importance of angiotensin-converting enzyme in pulmonary hypertensionW T Abraham, M V Raynolds, B Gottschall, et al.
Journal of the American College of Cardiology|July 26, 2008
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)William T Abraham, Gregg C Fonarow, Nancy M Albert, et al.
The American Journal of Cardiology|November 26, 2008
Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)Gregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Circulation|February 22, 2017
Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS SensorJ Thomas Heywood, Rita Jermyn, David Shavelle, et al.
Journal of Cardiac Failure|April 30, 2015
Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF)Mathew S Maurer, Philip B Adamson, Maria Rosa Costanzo, et al.
Immunity|December 1, 1996
Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activationB A Binstadt, K M Brumbaugh, C J Dick, et al.
Pageof 94

Showing results (631-640 of 932) with videos related to

Sort By:
Pageof 94
The Journal of Thoracic and Cardiovascular Surgery|January 3, 2007
Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failureCharles T Klodell, David C McGiffin, Barry K Rayburn, et al.
Journal of the American College of Cardiology|July 12, 2008
Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF programGregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Heart Rhythm|November 29, 2021
The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studiesEugene S Chung, Michael R Gold, William T Abraham, et al.
Journal of Cardiac Failure|November 13, 2007
Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HFGregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Cardiology|January 1, 1995
Importance of angiotensin-converting enzyme in pulmonary hypertensionW T Abraham, M V Raynolds, B Gottschall, et al.
Journal of the American College of Cardiology|July 26, 2008
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)William T Abraham, Gregg C Fonarow, Nancy M Albert, et al.
The American Journal of Cardiology|November 26, 2008
Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure)Gregg C Fonarow, William T Abraham, Nancy M Albert, et al.
Circulation|February 22, 2017
Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS SensorJ Thomas Heywood, Rita Jermyn, David Shavelle, et al.
Journal of Cardiac Failure|April 30, 2015
Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF)Mathew S Maurer, Philip B Adamson, Maria Rosa Costanzo, et al.
Immunity|December 1, 1996
Sequential involvement of Lck and SHP-1 with MHC-recognizing receptors on NK cells inhibits FcR-initiated tyrosine kinase activationB A Binstadt, K M Brumbaugh, C J Dick, et al.
Pageof 94